Prothena | PRTA - Current Liabilities


Prothena reported $11.66M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 25.5B 547M Jun/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Exelixis USD 361.93M 9.05M Jun/2026
Immunic USD 38.36M 7.74M Mar/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Prothena USD 11.66M 20.86M Jun/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026